Growing IL-18 field looks to enhance cell therapies via decoy evasion

Deals between major cancer cell therapy players and biotechs with strategies to promote IL-18 signaling unhampered by decoy receptors indicate the cytokine’s next wave of innovation will combine the two approaches.

Interest in IL-18’s capacity to boost tumor killing by immune cells has risen over the last five years through the convergence of multiple findings, including biomarker support for the cytokine’s role...